Connect with us

Business Wire

BioPharm International® Presents Webcasts on the Versatility of Light Scattering and the Exploration of Biotherapeutic Analysis

Business Wire

Published

on

Reading Time: 3 minutes

These separate webcasts will provide attendees with an improved understanding of the utility of dynamic light scattering and aggregate analysis and charge variant analysis using a native MS approach.

CRANBURY, N.J.–(BUSINESS WIRE)–#biopharmaceuticalsBioPharm International®, a digital resource of technical articles, technology reports, regulatory and business columns and expert commentary surrounding biopharmaceuticals, biotechnology and bioprocessing, will host “The Versatility of High Throughput Dynamic Light Scattering in Protein Characterization and Formulation Development” and “Native MS Aggregate and Charge Variant Analysis of Biotherapeutics” on Tuesday, Aug. 20 at 11 a.m. EDT.

“Understanding the efficiency of the latest practices within the realm of scientific research is essential,” said Michael J. Hennessey Jr., president of MJH Life Sciences™. “These webcasts will serve as an excellent resource for scientists, analysts and protein engineers alike to appreciate and adopt these new practices.

“The Versatility of High Throughput Dynamic Light Scattering in Protein Characterization and Formulation Development” will be co-hosted by LC GC®, a leading multimedia platform of peer-reviewed technical information on the field of chromatography and the separation sciences. Presented by Katherine E. Bowers, principal scientist at Fujifilm Diosynth Biotechnologies U.S.A. Inc, this webcast will use a series of case studies to focus on the versatility and utility of dynamic light scattering (DLS) in therapeutic protein characterization and formulation development. The webcast will allow attendees to discover the use of thermal ramp DLS to monitor the stability of multiple protein formulations in a single experiment, learn how isothermal DLS monitoring of protein formulations can rank stability and compliment other biophysical methods such as differential scanning calorimetry, and much more.

Native MS for Aggregate and Charge Variant Analysis of Biotherapeutics” will be led by Chris Nortcliffe, Ph.D., applications specialist at SCIEX. As a specialist in biologics and structural biology, Nortcliffe will explore the fundamentals in size exclusion chromatography (SEC) and ion exchange chromatography for biotherapeutic characterization. Participants will gain insight on the effects of mobile phase conditions and chromatographic parameters in aggregate analysis by native SEC, as well as come to understand the determination of acidic and basic variants of monoclonal antibodies using native weak cation exchange chromatography.

To register for Native MS for Aggregate and Charge Variant Analysis of Biotherapeutics,” click here.

To register for “The Versatility of High Throughput Dynamic Light Scattering in Protein Characterization and Formulation Development,” click here.

About BioPharm International®

BioPharm International® integrates the science and business of biopharmaceutical research, development and manufacturing. BioPharm International® is a multimedia peer-reviewed resource on technical solutions to help biopharmaceutical professionals succeed in their work. This digital platform features peer-reviewed papers, technical articles, technology reports, regulatory and business columns, and expert commentary surrounding biopharmaceuticals, biotechnology, bioprocessing and all topics related to pharma manufacturing. BioPharm International® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.

About LC GC®

LC GC® is the largest global chromatography multimedia platform dedicated to the separation sciences. Combining all the resources of the regional editions (LC GC North America, LC GC Europe and LC GC Asia-Pacific), chromatographyonline.com is the premier global digital resource for unbiased, peer-reviewed technical information on the field of chromatography and the separation sciences. LC GC® delivers practical information that can help lab professionals become more proficient in the use of chromatographic techniques and instrumentation, thereby making laboratories more productive and businesses around the world more successful. LC GC® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.

Contacts

Media Contacts:

Michelle Wood / 609-325-4801

mwood@mmhgroup.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.

Business Wire

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Textron, Inc.

Business Wire

Published

on

Reading Time: 1 minute

OKLAHOMA CITY–(BUSINESS WIRE)–#ClassAction–Federman & Sherwood announces that on August 22, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Textron, Inc. (NYSE: TXT). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is January 31, 2018 through October 17, 2018.

To learn how to participate in this action, please visit https://www.federmanlaw.com/blog/federman-sherwood-announces-the-filing-of-a-securities-class-action-lawsuit-against-textron-inc/

Plaintiff seeks to recover damages on behalf of all Textron, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, October 21, 2019 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:

Robin Hester

FEDERMAN & SHERWOOD

10205 North Pennsylvania Avenue

Oklahoma City, OK 73120

Email to: rkh@federmanlaw.com

Or, visit the firm’s website at www.federmanlaw.com

Contacts

Robin Hester 

FEDERMAN & SHERWOOD 

rkh@federmanlaw.com

Continue Reading

Business Wire

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Textron, Inc.

Business Wire

Published

on

Reading Time: 1 minute

OKLAHOMA CITY–(BUSINESS WIRE)–#ClassAction–Federman & Sherwood announces that on August 22, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Textron, Inc. (NYSE: TXT). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is January 31, 2018 through October 17, 2018.

To learn how to participate in this action, please visit https://www.federmanlaw.com/blog/federman-sherwood-announces-the-filing-of-a-securities-class-action-lawsuit-against-textron-inc/

Plaintiff seeks to recover damages on behalf of all Textron, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, October 21, 2019 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:

Robin Hester

FEDERMAN & SHERWOOD

10205 North Pennsylvania Avenue

Oklahoma City, OK 73120

Email to: rkh@federmanlaw.com

Or, visit the firm’s website at www.federmanlaw.com

Contacts

Robin Hester 

FEDERMAN & SHERWOOD 

rkh@federmanlaw.com

Continue Reading

Business Wire

UBS Group AG and Merrill Lynch Are Being Investigated for Sales of Unsuitable Investments

Business Wire

Published

on

Reading Time: 1 minute

OKLAHOMA CITY–(BUSINESS WIRE)–#ClassAction–Federman & Sherwood has initiated an investigation of UBS Group AG and Merrill Lynch. UBS Group AG (NYSE: UBS) sold a very complex investment strategy called Yield Enhancement Strategy (YES). Merrill Lynch sold a similar product called the Collateral Yield Enhancement Strategy (CYES). The primary strategy of these complex trading strategies, both of which utilized leverage and borrowed money putting investors at further risk, is called an “Iron Condor”. This involves simultaneously entering into multiple option positions at the same time while essentially betting on the volatility of the market and certain indexes. These products, which had very high commissions, were peddled to retail customers with a focus on widows, retirees and elderly looking for yield. The brokerage firms apparent excuse is that the retail customers were given offering documents that “fully” explained the investments and therefore accepted the risk while relying on their brokers assurances that the investments were suitable. Federman & Sherwood, a boutique securities litigation law firm with over 37 years of experience, is investigating both UBS and Merrill Lynch for their sales practices in selling unsuitable investments.

If you have information about UBS or Merrill Lynch sales practices or invested in these highly-leveraged products and lost money, please contact William Federman at (405) 235-1560 or by email wbf@federmanlaw.com. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.

Contacts

Robin Hester

FEDERMAN & SHERWOOD

Telephone: (405) 235-1560

Email to: adb@federmanlaw.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Business Wire41 mins ago

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Textron, Inc.

Business Wire41 mins ago

Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Textron, Inc.

Business Wire2 hours ago

UBS Group AG and Merrill Lynch Are Being Investigated for Sales of Unsuitable Investments

IT Industry8 hours ago

Next-Generation Sequencing (NGS) Market 2019 Global Insights Type of Sequencing, Product Type, End User, Application, Competitive Landscape, Key Strategies & Growth Prospect: Orbis Research

IT Industry9 hours ago

Cosmeceuticals Market to grow at 8.81% CAGR to hit $85 billion by 2024 – Global Insights on Emerging Trends, Product Type (Skin Care, Hair Care & Lip Care), Distribution Channel, Key Strategies & Growth Prospect: Orbis Research

IT Industry10 hours ago

Carrier Screening Market Global Insights on Test Type, Disease Type, Restraints, Competitive Landscape and 2019 Top Trends: Orbis Research

IT Industry10 hours ago

Carrier Screening Market Global Insights on Test Type, Disease Type, Restraints, Competitive Landscape and 2019 Top Trends: Orbis Research

IT Industry10 hours ago

Influenza Diagnostics Market Estimated to grow at 6.83% to reach $731.97 Million by 2024- Global Insights on Test Type (Traditional Diagnostic Test and Molecular Diagnostic Assay), Restraints, Drivers and Future Trends: Orbis Research

Blockchain PR10 hours ago

Fantasy Sports Market Estimated to grow at 13.2% to reach $33200 Mn by 2025-Key Insights on Revenue (Value), Potential Application, Economic Fluctuations, Growth Rate and Future Trends: Orbis Research

Business Wire12 hours ago

FEDEX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FedEx Corporation

Follow our Tweets

Trending

Please turn AdBlock off